罗氏在季度管道清理中放弃中期乙型肝炎和眼病项目

StephenW

罗氏在季度管道清理中放弃中期乙型肝炎和眼病项目
尼克·保罗·泰勒
2022 年 10 月 18 日 05:55
Rochehepatitis Bage 相关性黄斑变性管道
罗氏大楼
罗氏还更新了其计划申请批准 tiragolumab 治疗食管癌的目标时间。 （塞巴斯蒂安·博宗/法新社通过盖蒂图片社拍摄）

罗氏已将剪刀带入其临床开发管道，在其研究资产的季度剔除中剪断了乙型肝炎病毒和地理萎缩潜在治疗方法的第二阶段研究。

从第 2 阶段移除的乙型肝炎候选药物 (PDF) 是 RG7907，一种核心蛋白变构调节剂，也称为 RO7049389。罗氏在 2020 年将候选药物带入中期开发阶段，因为有证据表明这种小分子通过破坏其核衣壳的组装和诱导功能性核心蛋白的消耗来抑制病毒的复制。

在审查了 2019 年的第一阶段数据后，罗氏认为该候选药物可能是能够治愈乙型肝炎感染的药物分子组合的一部分。三年后，罗氏放弃了这一前景。该行动是在第一阶段试验完成数月后和在第二阶段研究期间进行的，该研究旨在以两种组合测试候选人。

即使在 RG7907 停用后，罗氏仍然是寻求乙型肝炎治愈的参与者。多方案第 2 阶段具有其他候选药物的多种组合，例如使用 Novo Nordisk 的 Dicerna Pharmaceuticals 技术的 siRNA 前景 RG6346 和 TLR7 激动剂 RG7854。

StephenW

Roche drops midphase hepatitis B and eye disease programs in quarterly pipeline clearout
By Nick Paul Taylor
Oct 18, 2022 05:55am
Rochehepatitis Bage-related macular degenerationpipeline
Roche building
Roche also updated the targeted timing of its planned filing for approval of tiragolumab in esophageal cancer. (Photo by SEBASTIEN BOZON/AFP via Getty Images)

Roche has taken the scissors to its clinical development pipeline, snipping off phase 2 studies of potential treatments for hepatitis B virus and geographic atrophy in the quarterly cull of its investigational assets.

The hepatitis B candidate removed (PDF) from phase 2 is RG7907, a core protein allosteric modulator that is also known as RO7049389. Roche took the drug candidate into midphase development in 2020 on the strength of evidence the small molecule inhibits replication of the virus by disrupting the assembly of its nucleocapsids and inducing the depletion of functional core proteins.

After reviewing phase 1 data in 2019, Roche felt the candidate could be part of a combination of drug molecules capable of curing hepatitis B infection. Three years later, Roche has dropped the prospect. The action comes months after the completion of a phase 1 trial and during a phase 2 study set up to test the candidate in two combinations.

Roche remains a player in the pursuit of a hepatitis B cure even after the defenestration of RG7907. The multi-regimen phase 2 features multiple combinations of other candidates, such as the siRNA prospect RG6346, which uses technology from Novo Nordisk’s Dicerna Pharmaceuticals, and the TLR7 agonist RG7854.